GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » Accumulated other comprehensive income (loss)

Hepion Pharmaceuticals (FRA:336) Accumulated other comprehensive income (loss) : €0.01 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Hepion Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Hepion Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was €0.01 Mil.

Hepion Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2023 (€-0.09 Mil) to Dec. 2023 (€-0.07 Mil) and increased from Dec. 2023 (€-0.07 Mil) to Mar. 2024 (€0.01 Mil).

Hepion Pharmaceuticals's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€-0.09 Mil) but then increased from Dec. 2022 (€-0.09 Mil) to Dec. 2023 (€-0.07 Mil).


Hepion Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Hepion Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals Accumulated other comprehensive income (loss) Chart

Hepion Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.09 -0.07

Hepion Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.08 -0.09 -0.07 0.01

Hepion Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.


Hepion Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Hepion Pharmaceuticals (FRA:336) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » Accumulated other comprehensive income (loss)
Traded in Other Exchanges
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals (FRA:336) Headlines

No Headlines